The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 11, 2018
Filed:
Apr. 03, 2015
Applicant:
National Cerebral and Cardiovascular Center, Suita-shi, Osaka, JP;
Inventors:
Assignee:
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Suita-Shi, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/18 (2006.01); A01N 41/06 (2006.01); C07C 311/28 (2006.01); C07C 311/29 (2006.01); A61K 31/5375 (2006.01); A61K 9/00 (2006.01); A61K 31/197 (2006.01); A61K 31/216 (2006.01); A61K 31/277 (2006.01); A61K 31/341 (2006.01); A61K 31/357 (2006.01); A61K 31/381 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/42 (2006.01); A61K 31/421 (2006.01); A61K 31/423 (2006.01); A61K 31/426 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/445 (2006.01); A61K 31/4465 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/27 (2006.01); A61K 31/36 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/428 (2006.01); A61K 31/438 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/472 (2006.01); A61K 31/554 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5375 (2013.01); A61K 9/0053 (2013.01); A61K 31/18 (2013.01); A61K 31/192 (2013.01); A61K 31/197 (2013.01); A61K 31/216 (2013.01); A61K 31/27 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/357 (2013.01); A61K 31/36 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/404 (2013.01); A61K 31/4035 (2013.01); A61K 31/41 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/42 (2013.01); A61K 31/421 (2013.01); A61K 31/423 (2013.01); A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/438 (2013.01); A61K 31/44 (2013.01); A61K 31/4402 (2013.01); A61K 31/445 (2013.01); A61K 31/4406 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/4465 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/472 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/554 (2013.01); A61K 45/06 (2013.01);
Abstract
Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.